MGMT methylation: A marker of response to temozolomide in low-grade gliomas

Annals of Neurology

Volumn 60, Issue 6, 2006, Pages 740-743

  Everhard, Sibille ^a,b   Kaloshi, Gentian ^b,c   Crinière, Emmanuelle ^a,b   Benouaich Amiel, Alexandra ^b,c   Lejeune, Julie ^b,c   Marie, Yannick ^a,b   Sanson, Marc ^a,b,c   Kujas, Michèle ^b,c   Mokhtari, Karima ^b,c   Hoang Xuan, Khê ^a,b,c   Delattre, Jean Yves ^a,b,c   Thiller, Joèlle ^a,b  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER SURVIVAL; DISEASE SEVERITY; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG RESPONSE; ENZYME ANALYSIS; EVALUATION; GLIOMA; HUMAN; MAJOR CLINICAL STUDY; METHYLATION; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROMOTER REGION;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; DACARBAZINE; DISEASE PROGRESSION; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC MARKERS; GLIOMA; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROMOTER REGIONS (GENETICS); SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P14ARF;

EID: 33846009775     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.21044     Document Type: Article

References (17)

1. Hegi ME, Diserens AC, Godard S, et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004;10: 1871-1874.
2. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003.
3. Paz MF, Yaya-Tur R, Rojas-Marcos I, et al. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res 2004;10:4933-4938.
4. Watanabe T, Nakamura M, Kros JM, et al. Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas. Acta Neuropathol (Berl) 2002;103:267-275.
5. Dong SM, Pang JC, Poon WS, et al. Concurrent hypermethylation of multiple genes is associated with grade of oligodendroglial tumors. J Neuropathol Exp Neurol 2001;60:808-816.
6. Mollemann M, Wolter M, Felsberg J, et al. Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer 2005;113:379-385.
7. Alonso ME, Bello MJ, Gonzalez-Gomez P, et al. Aberrant promoter methylation of multiple genes in oligodendrogliomas and ependymomas. Cancer Genet Cytogenet 2003;144:134-142.
8. Hoang-Xuan K, Capelle L, Kujas M, et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004;22:3133-3138.
9. Palmisano WA, Divine KK, Saccomanno G, et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 2000;60:5954-5958.
10. Kujas M, Lejeune J, Benouaich-Amiel A, et al. Chromosome 1p loss: a favorable prognostic factor in low-grade gliomas. Ann Neurol 2005;58:322-326.
11. Behin A, Hoang-Xuan K, Carpentier AF, Delattre JY. Primary brain tumours in adults. Lancet 2003;361:323-331.
12. Collins VP. Brain tumours: classification and genes. J Neurol Neurosurg Psychiatry 2004;75(suppl 2):ii2-ii11.
13. Komine C, Watanabe T, Katayama Y, et al. Promoter hypermethylation of the DNA repair gene O6-methylguanine-DNA methyltransferase is an independent predictor of shortened progression free survival in patients with low-grade diffuse astrocytomas. Brain Pathol 2003;13:176-184.
14. Levin N, Lavon I, Zelikovitsh B, et al. Progressive low-grade oligodendrogliomas: response to tentozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer 2006;106:1759-1765.
15. Esteller M, Garcia-Foncillas J, Andiott E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000;343: 1350-1354.
16. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998; 90:1473-1479.
17. van den Bent MJ, Looijenga LH, Langenberg K, et al. Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer 2003;97:1276-1284.